Phio Pharmaceuticals Corp (PHIO) - Net earnings per share (EPS TTM)
Patents for INTASYL and strict FDA oversight create significant barriers, as confirmed by the annual EPS TTM snapshot, where the value -1.27 determines this level. The stability of cold chain logistics ensures the integrity of the therapy. High demand in immuno-oncology and the potential for partnerships with industry behemoths open broad market prospects for Phio Pharmaceuticals (PHIO).
PHIO (RXi Pharmaceuticals): analytical breakdowns and indicator data
- current quotes and average value forecast:
- market capitalization indicators:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Phio Pharmaceuticals|PHIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Phio Pharmaceuticals|PHIO - Company Aggregate Debts|Debts to Book Capitalization PHIO|PHIO - Company Long-Term Liabilities|Company Short-Term Debts Phio Pharmaceuticals|Quick Liquidity Indicator phiopharma.com
- net income and valuation multiples indicators:
PHIO - Net Profit|Future Profit Phio Pharmaceuticals|PHIO - Market Price to Net Income Ratio|Forward P/E Multiple Phio Pharmaceuticals Corp|PHIO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple PHIO|PHIO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Phio Pharmaceuticals|PHIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months phiopharma.com|PHIO - Earnings per share growth in current year|Net earnings per share growth forecast for next year Phio Pharmaceuticals
- sales and revenue data:
Analysis of all company metrics:RXi Pharmaceuticals (PHIO)
For Phio Pharmaceuticals (PHIO), which develops RNA interference through scientific partnerships, this indicator serves as a measure of research capitalization efficiency. The metric is calculated as the ratio of total annual net income to the total number of shares. Analyzing the 12-month net income per share chart allows for the exclusion of the impact of share issuances. This price action reflects the real yield of each share, while a decline in the indicator signals risks of investment capital freezing.
Competitor analysis
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months STOK (Stoke Therapeutics, Inc.)|Net earnings per share for the last 12 months BLFS|Net earnings per one share for the last twelve months Wave Pharma WVE|Net earnings per share for the last 12 months MAZE (Maze Tx)|SION - Net earnings per one share for the last twelve months|Prime Medicine - Net earnings per share for the last 12 months|Taysha Gene Therapies Inc (TSHA) - Net earnings per one share for the last twelve months|uniqure.com - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year MeiraGTx Corp (MGTX)|REGENXBIO (RGNX) - Earnings per share for the last twelve months|SLDB - Net earnings per share for the last four quarters|OCGN (ocugen.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Pacific Biosciences of California, Inc. PACB|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last four quarters Design Pharma|Net earnings per share (EPS TTM) RCKT (Rocket Corp)|FDMT - Net earnings per share for the last 12 months|Lexeo - Net earnings per share (EPS TTM)|KRRO - Net earnings per share (EPS TTM)|EDIT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months SLN|Net earnings per share for the last 12 months PRQR|Net earnings per one share for the last twelve months Codexis CDXS|Earnings per share for the last twelve months Sangamo BioSciences (SGMO)|Net earnings per share (EPS TTM) Nautilus Biotechnology Inc (NAUT)|Net earnings per share (EPS TTM) MGX (Metagenomi Inc.)|Precision BioSciences - Earnings per share for the last twelve months|generationbio.com - Net earnings per share (EPS TTM)|BOLD: Earnings per share for the last twelve months|XCUR (Exicure Corp) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months IMNN|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
